Monkeypox Vaccine: US FDA Eyes Dose-Sparing Strategy For Jynneos

 
• By Sue Sutter

Switching method of administration from subcutaneous to intradermal would increase by five-fold the number of doses of Bavarian Nordic’s vaccine available to combat the outbreak; an EUA declaration would be needed to make this change, FDA commissioner Robert Califf said.

Intradermal administration
US FDA is weighing a shift to intradermal administration as a way of stretching the Jynneos vaccine supply. • Source: Shutterstock

The US Food and Drug Administration is considering a dose-sparing strategy for Bavarian Nordic A/S’ monkeypox vaccine Jynneos that could increase by five-fold the number of doses available to combat the outbreak.

The proposed strategy would change the method of administration for Jynneos, the only FDA-approved vaccine to prevent monkeypox, from subcutaneous to intradermal administration.

More from Vaccines

More from Pink Sheet